Pleural Fluid Tumour Markers in Malignant Pleural Effusion with Inconclusive Cytologic Results

Antonângelo, Leila; Sales, Roberto Moura; Corá, Aline Pivetta; Acencio, Milena Marques Pagliarelli; Teixeira, Lisete R.; Vargas, Francisco Suso

doi:10.3747/co.22.2563

Cited by 43 publications

(49 citation statements)

References 18 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…When compared with the sensitivity and specificity of more advanced test such as tumour markers like CEA, CA15-3, CA125, and cyfra 21-1 in pleural fluid, the sensitivity and specificity of “cancer ratio” and “cancer ratio plus” were higher than these tests. The reported sensitivity and specificity of CEA, CA15-3, CA 125, and cyfra 21-1 were 0.65 and 0.97, 0.57 and 0.90, 0.68 and 0.83, and 0.53 and 0.79, respectively [9]. …”

Section: Discussionmentioning

confidence: 99%

“…In recent years, several more advanced assays have been developed to diagnose malignancy in a patient presenting with pleural effusion. Examples include measurement of tumour markers CEA, CA15-3, CA125, and cyfra 21-1 in pleural fluid and protein microarray technologies to differentiate malignant from TB effusion [9, 10]. Although these new techniques have potential, their use has not entered mainstream practice.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Differentiating Malignant from Tubercular Pleural Effusion by Cancer Ratio Plus (Cancer Ratio: Pleural Lymphocyte Count)

Verma

Dagaonkar

Marshall

et al. 2016

Canadian Respiratory Journal

View full text Add to dashboard Cite

Background. We performed prospective validation of the cancer ratio (serum LDH : pleural ADA ratio), previously reported as predictive of malignant effusion retrospectively, and assessed the effect of combining it with “pleural lymphocyte count” in diagnosing malignant pleural effusion (MPE). Methods. Prospective cohort study of patients hospitalized with lymphocyte predominant exudative pleural effusion in 2015. Results. 118 patients, 84 (71.2%) having MPE and 34 (28.8%) having tuberculous pleural effusion (TPE), were analysed. In multivariate logistic regression analysis, cancer ratio, serum LDH : pleural fluid lymphocyte count ratio, and “cancer ratio plus” (ratio of cancer ratio and pleural fluid lymphocyte count) correlated positively with MPE. The sensitivity and specificity of cancer ratio, ratio of serum LDH : pleural fluid lymphocyte count, and “cancer ratio plus” were 0.95 (95% CI 0.87–0.98) and 0.85 (95% CI 0.68–0.94), 0.63 (95% CI 0.51–0.73) and 0.85 (95% CI 0.68–0.94), and 97.6 (95% CI 0.90–0.99) and 94.1 (95% CI 0.78–0.98) at the cut-off level of >20, >800, and >30, respectively. Conclusion. Without incurring any additional cost, or requiring additional test, effort, or time, cancer ratio maintained and “cancer ratio plus” improved the specificity of cancer ratio in identifying MPE in the prospective cohort.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Differentiating Malignant from Tubercular Pleural Effusion by Cancer Ratio Plus (Cancer Ratio: Pleural Lymphocyte Count)

Verma

Dagaonkar

Marshall

et al. 2016

Canadian Respiratory Journal

View full text Add to dashboard Cite

show abstract

“…[9][10][11][12][13] For example, CEA (CEACAM5) is widely used as a serum biomarker in colorectal carcinoma therapy and may be useful in monitoring pleural effusions with inconsistent cytologic results. 14,15 There is extensive evidence of PSG mRNA expression in non-trophoblastic tumors. [16][17][18][19][20][21] For example, in one study, PSG9 mRNA upregulation was detected in 78% (14/18) of FAP adenomas and 75% (45/60) of sporadic colorectal cancer cases tested.…”

Section: Introductionmentioning

confidence: 99%

Pregnancy-specific glycoprotein expression in normal gastrointestinal tract and in tumors detected with novel monoclonal antibodies

Houston

Williams

Roviš

et al. 2016

mAbs

View full text Add to dashboard Cite

(2016) Pregnancyspecific glycoprotein expression in normal gastrointestinal tract and in tumors detected with novel monoclonal antibodies, mAbs, 8:3, 491-500, DOI: 10.1080DOI: 10. /19420862.2015 To link to this article: https://doi.org/10. 1080/19420862.2015 ABSTRACTPregnancy-specific glycoproteins (PSGs) are immunoglobulin superfamily members related to the carcinoembryonic antigen-related cell adhesion molecule (CEACAM) family and are encoded by 10 genes in the human. They are secreted at high levels by placental syncytiotrophoblast into maternal blood during pregnancy, and are implicated in immunoregulation, thromboregulation, and angiogenesis. To determine whether PSGs are expressed in tumors, we characterized 16 novel monoclonal antibodies to human PSG1 and used 2 that do not cross-react with CEACAMs to study PSG expression in tumors and in the gastrointestinal (GI) tract using tissue arrays and immunohistochemistry. Staining was frequently observed in primary squamous cell carcinomas and colonic adenocarcinomas and was correlated with the degree of tumor differentiation, being largely absent from metastatic samples. Staining was also observed in normal oesophageal and colonic epithelium. PSG expression in the human and mouse GI tract was confirmed using quantitative RT-PCR. However, mRNA expression was several orders of magnitude lower in the GI tract compared to placenta. Our results identify a non-placental site of PSG expression in the gut and associated tumors, with implications for determining whether PSGs have a role in tumor progression, and utility as tumor biomarkers.

show abstract

“…37,38 Different results were found for ascites: a positive result for malignancy was obtained in four of the seven patients with a final diagnosis of cancer in whom peritoneal fluid had been analysed. 37,38 Different results were found for ascites: a positive result for malignancy was obtained in four of the seven patients with a final diagnosis of cancer in whom peritoneal fluid had been analysed.…”

Section: Discussionmentioning

confidence: 99%

Polyserositis: a diagnostic challenge

Losada

González-Moreno

Roda

et al. 2018

Internal Medicine Journal

View full text Add to dashboard Cite

show abstract

Pleural Fluid Tumour Markers in Malignant Pleural Effusion with Inconclusive Cytologic Results

Abstract: BackgroundThe presence of tumour cells in pleural fluid or tissue defines an effusion as malignant. Cytology

Cited by 43 publications

References 18 publications

Differentiating Malignant from Tubercular Pleural Effusion by Cancer Ratio Plus (Cancer Ratio: Pleural Lymphocyte Count)

Differentiating Malignant from Tubercular Pleural Effusion by Cancer Ratio Plus (Cancer Ratio: Pleural Lymphocyte Count)

Pregnancy-specific glycoprotein expression in normal gastrointestinal tract and in tumors detected with novel monoclonal antibodies

Polyserositis: a diagnostic challenge

Contact Info

Product

Resources

About